The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KMDA | +30.74% | -16.53% | -3.55% | -24% |
| S&P | +14.5% | +93.32% | +14.09% | +383% |
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
The biotech specializes in plasma-derived protein therapeutics.
Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $44.75M | 5.4% |
| Gross Profit | $18.93M | -0.1% |
| Gross Margin | 42.30% | -2.3% |
| Market Cap | $445.66M | 60.8% |
| Market Cap / Employee | $1.06M | 0.0% |
| Employees | 420 | 11.1% |
| Net Income | $7.38M | 66.7% |
| EBITDA | $10.83M | 22.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $65.99M | 16.7% |
| Accounts Receivable | $30.50M | 16.3% |
| Inventory | 82.1 | 4.3% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $9.55M | 35.2% |
| Short Term Debt | $1.87M | 24.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.29% | 0.8% |
| Return On Invested Capital | 3.15% | -2.1% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $6.03M | -44.6% |
| Operating Free Cash Flow | $8.06M | -41.8% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 19.66 | 24.12 | 23.58 | 23.57 | 30.66% |
| Price to Book | 1.18 | 1.33 | 1.47 | 1.77 | 57.34% |
| Price to Sales | 1.95 | 2.17 | 2.27 | 2.64 | 42.68% |
| Price to Tangible Book Value | 1.18 | 1.33 | 2.99 | 2.01 | 78.86% |
| Price to Free Cash Flow TTM | 9.77 | 9.47 | 10.37 | 22.30 | -15.53% |
| Enterprise Value to EBITDA | 29.03 | 28.83 | 27.50 | 36.33 | 35.18% |
| Free Cash Flow Yield | 10.2% | 10.6% | 9.6% | 4.5% | 18.38% |
| Return on Equity | 6.4% | 5.7% | 6.4% | 7.4% | 5.60% |
| Total Debt | $11.16M | $11.06M | $11.10M | $11.42M | 33.37% |
KMDA earnings call for the period ending September 30, 2020.
KMDA earnings call for the period ending June 30, 2020.
KMDA earnings call for the period ending March 31, 2020.
KMDA earnings call for the period ending December 31, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
